Crizotinib approved for ROS1 + lung cancer

On March 11 the FDA approved the selling of Crizotinib for patients with ROS1 mutations in lung cancer. The ORR was 66% and the median DOR was 18.3 months. Safety profile was similar to that in ALK + patients.

This entry was posted in crizotinib - Xalkori from Pfizer, Lung cancer, Regulatory applications & approvals. Bookmark the permalink.

Leave a Reply